This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Occurence of Inflammation and Oxidative Stress in Lung Diseases

This study has been completed.
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Maastricht University Medical Center Identifier:
First received: July 19, 2007
Last updated: February 22, 2017
Last verified: February 2008

Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities.

The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD

Interstitial Lung Diseases Sarcoidosis Idiopathic Pulmonary Fibrosis COPD

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants

Resource links provided by NLM:

Further study details as provided by Maastricht University Medical Center:

Biospecimen Retention:   Samples With DNA
blood samples were collected

Enrollment: 76
Study Start Date: September 2005
Study Completion Date: June 2006
21 onset patients, non-treated
15 IPF patients, partially treated
15 COPD patients within 24 hours after their last exacerbation
25 healthy controls, matched for age and gender

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
lung patients visiting the out-patient clinic of the Academic Hospital Maastricht

Inclusion Criteria:

  • clinical diagnosis of pulmonary sarcoidosis, IPF or COPD
  • no treatment for sarcoidosis
  • last exacerbation not more than 24 hours ago for COPD
  • healthy controls
  • no smoking for sarcoidosis and IPF

Exclusion Criteria:

  • pregnancy
  • use of vitamins or food supplements
  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00512967

Maastricht University
Maastricht, Netherlands, 6224 LH
Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Study Chair: Aalt Bast, PhD Maastricht University
Principal Investigator: Agnes W Boots, PhD Maastricht University
Study Director: Guido R Haenen, PhD Maastricht University
  More Information

Responsible Party: Dr. A.W. Boots, Maastricht University Identifier: NCT00512967     History of Changes
Other Study ID Numbers: MEC 03-112
Study First Received: July 19, 2007
Last Updated: February 22, 2017

Keywords provided by Maastricht University Medical Center:
oxidative stress

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs processed this record on September 21, 2017